http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#Head http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#assertion http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#provenance http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#pubinfo http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00959 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association http://www.w3.org/2000/01/rdf-schema#label when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis serum sickness transfusion reactions dermatologic diseases bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevens johnson syndrome endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis systemic therapy and ulcerative colitis hematologic disorders acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamond blackfan anemia pure red cell aplasia select cases of secondary thrombocytopenia miscellaneous trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy neoplastic diseases for palliative management of leukemias and lymphomas nervous system acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy ophthalmic diseases sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids renal diseases to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus respiratory diseases berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus see warnings methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon ganglia http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00959 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#provenance http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#pubinfo http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#sig http://purl.org/nanopub/x/hasSignature H5TC0AIa5GUxKfpZqoI07giGioejaPv56AO0QKNa+lY907x3wX6h7RbchvpziaOpz95SR4Jq9iHnbQCXWHmypgB/rMMPgpyi1z32Xmtq4Mn32Bd3FfaX6Gvx2ovN/pnNmC3IP5OQ1kEL3q8QFAqyCrpaq2DojcCl2A7GDG0SUxs= http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://purl.org/dc/terms/created 2021-06-12T16:18:12.333+02:00 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAQALY4mZPe7Jh7TGLnvxubLIG-WCmXqxu5Gv-cuOtT14 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs